El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
AbbVie Inc
Cerrado
SectorSalud
225.37 -0.98
Resumen
Variación precio
24h
Mínimo
223.45
Máximo
227.69
Ingresos | 1.6B 1.8B |
|---|---|
Ventas | 842M 17B |
P/B Media del Sector | 95.971 61.417 |
BPA | 2.71 |
Rentabilidad por dividendo | 2.89 |
Margen de beneficio | 10.928 |
Empleados | 57,000 |
EBITDA | 13B 16B |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +11.33% upside |
Rentabilidad por dividendo Media del Sector | 2.89% 2.40% |
|---|---|
Próximas Ganancias | 24 abr 2026 |
Fecha Próximo Dividendo | 15 may 2026 |
Próxima Fecha de Ex Dividendo | 15 abr 2026 |
Capitalización de Mercado | 3.4B 402B |
|---|---|
Apertura anterior | 226.35 |
Cierre anterior | 225.37 |
Puntuación técnica
By Trading Central
Confianza
Weak Bullish Evidence
AbbVie Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
AbbVie Inc Esperado
Precio Objetivo
By TipRanks
11.33% repunte
Estimación a 12 meses
Media 253.47 USD 11.33%
Máximo 299 USD
Mínimo 223 USD
De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de AbbVie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Live chat